Skip to main content
Log in

Characteristics and trends of POBA in current DES Era

  • Original Article
  • Published:
Cardiovascular Intervention and Therapeutics Aims and scope Submit manuscript


The aim of this study is to clarify the characteristics and trends of POBA in current drug-eluting stent (DES) era. We examined retrospectively the cases of POBA performed in our institute during the years from 2008 to 2012. For control, bare metal stents (BMS) and DES implantation done in 2011 were analyzed. During the period, 85 cases of POBA, 63 BMS and 132 DES were identified. In the result, the rate of restenosis in POBA was significantly higher than BMS and DES (39.7, 14.9, 3.7 %, POBA, BMS, DES, respectively, p < 0.001). We assumed three categories depending on the reasons for selecting POBA. (1) Stent delivery failure or expected difficulty of stent delivery due to calcification, etc. (n = 14), (2) intervention for in-stent restenosis or stent thrombosis (n = 34), (3) successful POBA applied to small vessels without complication (n = 14). According to it, category 1 showed significantly high probability of restenosis compared with others [(1) 10/14, 71.4 %, (2) 12/34, 35.3 %, 3; 2/14, 14.3 %, p < 0.05]. In addition, category 3 showed nearly as good as BMS. Balloons used in POBA contained 32 non-compliant balloons and 14 scoring balloons, whereas 30 were semi-compliant balloons only. ACC/AHA lesion type B2/C was 85.7, 45.7 and 50.0 %, and cases treated only with semi-compliant balloon were 57.1, 14.3, 92.9 % (category (1), (2) and (3), respectively, both p < 0.05). Therefore, this fact shows that a case of small vessel of which diameter is less than 2.5 mm would have a favorable outcome with POBA when treated well only with semi-compliant balloon under the current DES era.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others


  1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–23.

    Article  CAS  PubMed  Google Scholar 

  2. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583–91.

    Article  CAS  PubMed  Google Scholar 

  3. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–91.

    Article  CAS  PubMed  Google Scholar 

  4. Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stentimplantation. Circulation. 2007;115:2842–7.

    Article  PubMed  Google Scholar 

  5. Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart. 2013;99:327–33.

    Article  PubMed  Google Scholar 

  6. MacIsaac AI, Bass TA, Buchbinder M, Cowley MJ, Leon MB, Warth DC. High speed rotational atherectomy: outcome in calcified and non calcified coronary artery lesions. J Am Coll Cardiol. 1995;26:731–6.

    Article  CAS  PubMed  Google Scholar 

  7. Sun Y, Li L, Su Q, Lu Y. Comparative efficacy and safety of drug-eluting stent and conventional therapies in coronary heart disease patients with in-stent restenosis: a meta-analysis. Cell Biochem Biophys. 2014;68:211–29.

    Article  CAS  PubMed  Google Scholar 

  8. Ministry of Health, Labour and Welfare, Japan. The outlook of national health care costs of Japan. 2011.

  9. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2012;7:1060–1.

    Article  PubMed  Google Scholar 

  10. Abizaid A, Costa JR Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 29 Apr 2014: pii: 20130827-06. [Epub ahead of print].

  11. Cannon LA, Simon DI, Kereiakes D, Jones J, Mehran R, Kusano H, et al. The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. Catheter Cardiovasc Interv. 2012;80:546–53.

    Article  PubMed  Google Scholar 

Download references


We would like to express our gratitude to staffs at cath lab, especially Mr. Kazuyuki Shimizu for their daily assistance. We have nothing to disclose any relationship with industry or other institutes for this paper.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Manabu Moriya.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moriya, M., Ishiwata, S., Fujimoto, Y. et al. Characteristics and trends of POBA in current DES Era. Cardiovasc Interv and Ther 30, 315–319 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: